NextCell Pharma AB
65G
Company Profile
Business description
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
Contact
Karolinska Institutet Science Park
Halsovagen 7
Huddinge14157
SWET: +46 87355595
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.00 | 54.60 | -0.59% |
| CAC 40 | 8,286.40 | 5.77 | 0.07% |
| DAX 40 | 26,003.32 | 163.99 | 0.63% |
| Dow JONES (US) | 53,686.11 | 624.16 | 1.18% |
| FTSE 100 | 10,831.52 | 75.07 | 0.70% |
| HKSE | 25,714.06 | 500.75 | 1.99% |
| NASDAQ | 26,584.06 | 366.23 | 1.40% |
| Nikkei 225 | 64,980.87 | 766.39 | 1.19% |
| NZX 50 Index | 13,974.18 | 128.00 | 0.92% |
| S&P 500 | 7,747.71 | 81.11 | 1.06% |
| S&P/ASX 200 | 9,005.90 | 64.30 | -0.71% |
| SSE Composite Index | 3,939.77 | 2.31 | -0.06% |